Neurologic Involvement in Val-122 Ile Familial Amyloidosis (P1.026)
Sami Khella(University of Lisbon), Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Brian Drachman(Penn Presbyterian Medical Center), Daniel P. Judge(Medical University of South Carolina), Michael Polydefkis(Université Paris-Sud), Patricia Divito(University of Pennsylvania), Thomas H. Brannagan(Columbia University)
Cited by 1
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
|Heart Rhythm|2011|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k